Inovalon Holdings Inc (NASDAQ:INOV) – Investment analysts at William Blair increased their FY2017 earnings estimates for Inovalon in a research note issued to investors on Monday, Zacks Investment Research reports. William Blair analyst R. Daniels now expects that the technology company will post earnings of $0.27 per share for the year, up from their prior forecast of $0.25.
Inovalon (NASDAQ:INOV) last released its earnings results on Wednesday, November 1st. The technology company reported $0.09 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.08 by $0.01. The firm had revenue of $115.90 million during the quarter, compared to analysts’ expectations of $114.79 million. Inovalon had a net margin of 4.07% and a return on equity of 4.63%. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.10 EPS.
Inovalon (INOV) opened at $13.90 on Wednesday. The company has a market cap of $2,042.21, a price-to-earnings ratio of 115.84, a P/E/G ratio of 3.45 and a beta of 1.23. Inovalon has a one year low of $10.45 and a one year high of $17.80. The company has a debt-to-equity ratio of 0.31, a quick ratio of 5.62 and a current ratio of 5.62.
Several institutional investors have recently made changes to their positions in the stock. Black Creek Investment Management Inc. increased its position in shares of Inovalon by 11.8% during the 2nd quarter. Black Creek Investment Management Inc. now owns 10,925,250 shares of the technology company’s stock worth $143,667,000 after purchasing an additional 1,152,815 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Inovalon by 3.1% during the 2nd quarter. Vanguard Group Inc. now owns 4,960,754 shares of the technology company’s stock worth $65,234,000 after purchasing an additional 151,473 shares in the last quarter. Neuberger Berman Group LLC increased its position in shares of Inovalon by 3.1% during the 3rd quarter. Neuberger Berman Group LLC now owns 1,955,690 shares of the technology company’s stock worth $33,345,000 after purchasing an additional 58,447 shares in the last quarter. State Street Corp increased its position in shares of Inovalon by 59.1% during the 2nd quarter. State Street Corp now owns 1,151,392 shares of the technology company’s stock worth $15,140,000 after purchasing an additional 427,528 shares in the last quarter. Finally, Senvest Management LLC increased its position in shares of Inovalon by 138.6% during the 3rd quarter. Senvest Management LLC now owns 1,009,700 shares of the technology company’s stock worth $17,215,000 after purchasing an additional 586,500 shares in the last quarter. Institutional investors and hedge funds own 28.08% of the company’s stock.
In related news, President Robert A. Wychulis sold 85,828 shares of the stock in a transaction dated Tuesday, December 5th. The shares were sold at an average price of $15.54, for a total transaction of $1,333,767.12. Following the completion of the sale, the president now owns 466,286 shares in the company, valued at approximately $7,246,084.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Shauna L. Vernal sold 5,908 shares of the stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $16.01, for a total transaction of $94,587.08. Following the sale, the insider now owns 47,309 shares of the company’s stock, valued at approximately $757,417.09. The disclosure for this sale can be found here. Corporate insiders own 48.28% of the company’s stock.
Inovalon Company Profile
Inovalon Holdings, Inc (Inovalon) is a technology company. The Company provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models to the healthcare industry. Leveraging large-scale data interconnectivity capabilities, unparalleled proprietary data sets, advanced analytics, data-driven intervention systems, and subject matter expertise, Inovalon enables the assessment and improvement of clinical and quality outcomes and financial performance across the healthcare ecosystem.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovalon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalon and related companies with MarketBeat.com's FREE daily email newsletter.